Skip to main content

Advertisement

Table 1 Clinical features and survival of study participants (N = 115)

From: Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma

Clinical features N (%) Survival
1 yr.(%) 2 yrs. (%) p
Gender
 Male 88 (76.52) 63.67 38.98  
 Female 27 (23.48) 62.96 57.89 0.523
Age (y.o)
 <60 37 (32.17) 56.76 29.63  
60 78 (74.26) 66.67 45.28 0.207
ECOG
 0 49 (42.61) 75.51 54.29  
 1 53 (46.09) 58.49 36.36  
 2 13 (11.3) 46.15 20 0.118
Child-Pugh score
 A 104 (90.43) 68.27 47.14  
 B 11 (9.57) 27.27 12.5 <0.001
AJCC stage (7th)
 I 21 (18.26) 85.71 78.57  
 II 18 (15.65) 72.22 60  
 IIIA 26 (22.61) 69.23 40  
 IIIB 27 (23.48) 37.03 11.11  
 IIIC 3 (2.61) 100 0  
 IV 20 (17.39) 55 37.5 0.001
BCLC
 A 12 (10.44) 83.33 75  
 B 23 (20) 86.26 56.25  
 C 80 (69.56) 55 31.48 0.080
Tumor type
 Solitary 38 (33.04) 81.58 62.5  
 Multiple 69 (60) 56.52 31.25  
 Diffuse 8 (6.96) 37.5 33.33 <0.001
Tumor site
 Right 91 (79.13) 64.83 42.86  
 Left 14 (13.04) 53.33 38.46  
 Bilateral 10 (8.7) 60 0 0.506
Max. tumor diameter (cm)
4 40 (34.78) 75 55.17  
 > 4-9 47 (40.87) 68.82 36.67  
10 28 (23.48) 48.15 26.32 0.187
Portal vein tumor thrombosis
 Yes 34 (29.56) 35.29 12  
 No 81 (70.43) 75.31 53.7 <0.001
Hepatitis virus
 B 59 (51.3) 66.1 36.58  
 C 42 (36.52) 59.52 46.43  
 Non B non C 11 (9.57) 81.82 77.78  
 B + C 3 (2.61) 66.67 0 0.576
AFP Level (ng/ml)
20 41 (34.78) 82.93 62.5  
 > 20-400 31 (27.84) 51.61 17.65  
400 43 (37.39) 53.49 34.48 0.013
Biochemical changes
Albumin (g/dl) [N = 109]
 <3.5 26 (23.85) 46.15 31.81  
 ≥3.5 83 (76.15) 67.47 44.64 0.027
Alkaline Phosphatase (IU/L) [N = 104]
129 37 (35.58) 59.45 42.57  
 <129 67 (64.42) 64.18 36.95 0.893
Platelet (10^3/uL) [N = 109]
 <150 52 (47.71) 63.46 35  
150 57 (52.29) 68.42 48.65 0.291
BED
72 Gy10 65 (56.52) 56.92 28.2  
 73-88 Gy10 8 (6.96) 62.5 28.57  
89 Gy10 42 (36.52) 76.19 56.25 0.038
Previous treatment
 Yes 52 (45.22) 50 37.14  
 No 63 9(54.78) 55.56 43.18 0.584
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, AJCC American Joint Cancer Conference, BCLC Barcelona Clinic Liver Cancer Stage, AFP Alpha-Feto Protein, BED Biological Effective Dose